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Abstract
Structural allograft healing is limited because of a lack of vascularization and remodeling. To study
this we developed a mouse model that recapitulates the clinical aspects of live autograft and processed
allograft healing. Gene expression analyses showed that there is a substantial decrease in the genes
encoding RANKL and VEGF during allograft healing. Loss-of-function studies showed that both
factors are required for autograft healing. To determine whether addition of these signals could
stimulate allograft vascularization and remodeling, we developed a new approach in which rAAV
can be freeze-dried onto the cortical surface without losing infectivity. We show that combination
rAAV-RANKL- and rAAV-VEGF-coated allografts show marked remodeling and vascularization,
which leads to a new bone collar around the graft. In conclusion, we find that RANKL and VEGF
are necessary and sufficient for efficient autograft remodeling and can be transferred using rAAV to
revitalize structural allografts.
In contrast to soft tissue organ transplantation (i.e., heart, liver, kidney), which must be live
from a histocompatible donor, structural musculoskeletal grafts (i.e., bone, ligament) are often
derived from allogenic cadavers. Although this convenience makes structural allografts readily
available, the utility of these transplants is limited by their lack of viability. This is most evident
from experimental and clinical studies showing that fresh vascularized autogenous grafts are
vastly superior to allograft in terms of healing and remodeling1,2. Structural bone grafts used
to heal critical defects and bone fusions undergo a repair and remodeling process that closely
resembles fracture healing3. In live autograft healing, cells from both the graft and the host
contribute to mediate bony union4,5. In contrast, healing of a diaphyseal defect that has been
allografted can only be accomplished by invasion of the graft by host tissue to obtain a cortex-
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to-cortex union6. Following union, autografts continue to remodel as a result of osteoclastic
resorption of necrotic or disused cortical bone that is followed by osteoblastic formation of
new woven bone, which is later remodeled into stronger lamellar bone. In this way, autografts
are sustained through normal bone homeostasis. In contrast, once creeping callus from the host
calcifies on the cortex of an allograft, healing ceases, leaving a large segment of necrotic bone
that is unable to respond to normal mechanical loading. Thus, structural allografts have a
limited life span because microfractures that occur in them over time cannot be remodeled and
repaired, and negative outcomes include a 25–35% failure rate from infection, nonunion and
fracture7,8.
Two central issues that must be addressed to improve structural allografting are elucidation of
the factors that facilitate autograft healing and are absent in allografts and a method to introduce
these factors onto allografts. Toward resolving these issues, we have developed a mouse
femoral model that faithfully recapitulates the central features of clinical structural bone
grafting. Gene expression profiling studies showed that allografts are deficient in several
factors known to regulate vascular ingrowth of skeletal elements, osteogenesis, bone resorption
and remodeling. The two most notable factors were vascular endothelial growth factor (VEGF)
and receptor activator of nuclear factor κB ligand (RANKL), which are known to dominantly
regulate angiogenesis9 and osteoclastic bone resorption10, respectively, during skeletal repair.
Specifically, VEGF is expressed by the perichondrium and hypertrophic chondrocytes and
recruits endothelial cells to promote blood flow to the avascular tissue11. In addition to
essential nutrients, this blood supply brings in osteoclast precursors that differentiate in
response to RANKL expressed by stromal cells12. Based on this information we used in
vivo blockade and ex vivo gene transfer to show that RANKL and VEGF are necessary for
complete autograft healing. These findings support the hypothesis that RANKL and VEGF are
crucial factors for establishing remodeling of the cortical surface of the autografts and that
introduction of these factors onto allografts could result in bone resorption, neovascularization
and revitalization of the dead bone. Using a new approach to immobilize recombinant adeno-
associated virus (rAAV) onto the cortical surface of the allografts we show that RANKL and
VEGF signals are sufficient to revitalize processed cortical bone and could be a method to
sustain clinical allografts long term.
RESULTS
Mouse femoral autograft and allograft healing
To elucidate the cellular and molecular mechanisms that govern structural bone graft healing,
we developed an in vivo mouse model in which an ∼4-mm osteotomy of the middle of the
femoral diaphysis is performed and placed back into the original host as an autograft or
‘processed’ with fixation in alcohol and freezing and then transplanted as an allograft into an
allogenic host13. Figure 1 shows the radiographic and histologic healing of the two grafts.
Consistent with current knowledge, the autografts heal through endochondral bone formation
at the junctions with concomitant intramembranous bone formation derived from the
periosteum of the cortex of the graft. This bone formation results in a new bone collar of cortical
bone that partly or completely encircles the graft by 4 weeks. During this time, a new marrow
space is created between the new bone collar and the autograft, and accelerated osteoclastic
resorption of the graft occurs. In contrast, allografts heal by endochondral bone formation only.
At 2 weeks, cartilage derived from the host is observed creeping onto the ends of allografts.
Notably, the osteocartilaginous tissue seems to be separated from the periosteum by a fibrous
tissue reaction that partly or completely encases the allograft as part of a foreign body reaction
to it. By 4 weeks, healing is completed as a new cortical union at the graft-host junctions with
a large middle segment of necrotic bone that is completely devoid of osteoclast activity.
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Allografts are deficient in RANKL and VEGF
Over the last few years a wealth of information on the factors that regulate bone repair has
been generated from microarray gene expression profiling studies on fracture callus tissue14.
Based on this information, we performed a screen to identify dysregulated gene expression
between autografts and allografts by RT-PCR. The two factors that showed the most substantial
differential gene expression were Tnfsf11, which encodes RANKL, and Vegfa, which encodes
VEGF (Fig. 2). The expression of both factors peaked 10 d after autografting, when Tnfsf11
and Vegfa levels were twofold and fivefold higher than those observed in allograft tissue,
respectively. Whereas Tnfsf11 expression was deficient throughout the time course, Vegfa
expression seemed to be delayed and peaked on day 14 when endochondral ossification is
largely completed in stabilized fractures15. To follow up these findings, we performed
microarray studies using RNA isolated from day 10 autografts and allografts, and found,
according to the manufacturer's criteria, that these transcripts were present in the autografts
and absent in the allografts.
RANKL and VEGF in autograft healing
To assess the requirements of RANKL and VEGF signaling during autograft healing, we
performed in vivo blockade experiments using systemic and local approaches. First, the
autografted mice received control IgG, a soluble RANK decoy receptor (RANK:Fc) or
neutralizing antibodies specific for VEGF (Fig. 3a-d). We also assessed the effects of blocking
RANKL and VEGF locally by transducing the autografts ex vivo before implantation with
AAV-β-gal, AAV- osteoprotegerin (OPG), AAV-sFlt1 (soluble Flt1, the receptor for VEGF)
or a combination of AAV-OPG and AAV-sFlt1 (Fig. 3e-g). Radiographic and histologic
analyses of the autograft healing showed that disruption of either RANKL or VEGF signaling,
systemically or locally, significantly (P < 0.05) inhibited new bone formation on the cortical
surface of the grafts. Notably, dual blockade did not induce additional inhibitory effects,
indicating that these factors act in series to recruit and differentiate osteoclast progenitors to
the cortical surface.
Transduction efficiency of freeze-dried rAAV
With the hypothesis that addition of crucial signals to the cortical surface of allografts will lead
to autograft-like healing, we attempted to develop an approach to efficiently transfer these
signals. Previously, a gene-activated matrix was developed for this purpose, in which naked
plasmid DNA is immobilized onto osteoinductive materials16. Unfortunately, others and we
have been unable to achieve effective transduction efficiencies in our models using gene-
activated matrices. Based on the empirical advantages of rAAV vectors for orthopedic gene
therapy17, and the clinical potential of this vector18, we evaluated the effects of freeze-drying
and storage at −80 °C on rAAV transduction efficiency. Resuspension of rAAV in a sorbitol
solution facilitates its application to various organic and inorganic implant materials (Fig. 4a,b).
Application of the freeze-dried rAAV-β-gal to a monolayer of 293 human embryonic kidney
cells leads to efficient transduction as indicated by X-gal staining of the culture plates, which
showed a mosaic distribution of blue cells throughout the plates (Fig. 4c,d). No staining was
detected in control cultures without virus (Fig 4e). This result suggests that the rAAV
rehydrates and freely diffuses in the culture medium before infecting the cells. To assess the
effects of freeze-drying and storage on the immobilized rAAV, 5 × 107 transducing units of
rAAV-β-gal were directly placed on a monolayer of 293 cells, as a positive control; or freeze-
dried onto pins and stored at −80 °C for various times before addition to the monolayer (Fig.
4f). Notably, we were able to recover ∼100% of the β-galactosidase activity in all of the
samples. Thus, this coating process does not affect the infection capacity of the virus.
To assess the transduction efficiency of freeze-dried rAAV-β-gal in vivo, we performed a dose-
response experiment in which we coated femoral allografts with various doses of virus and
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transplanted them into mice. X-gal staining of histological sections showed that fibroblasts in
the inflammatory tissue between the bone and muscle were readily transduced (Fig. 4g,h). The
number of blue cells per section peaked at a dose of 5 × 107 particles/allograft. Thus, we used
this as our effective dose in our gain-of-function studies.
Revitalization of rAAV-RANKL and rAAV-VEGF coated allografts
To evaluate the effect of exogenous RANKL and VEGF on processed cortical bone healing,
allografts were coated with freeze-dried rAAV-β-gal, rAAV-RANKL, rAAV-VEGF or a
combination of rAAV-RANKL and rAAV-VEGF. First, we confirmed the in vivo target gene
expression following transplantation by determining serum levels of RANKL and VEGF over
time (Fig. 5a). By day 4 a substantial increase in VEGF was detected, which peaked at day 8
before returning to baseline levels at 3 weeks. Analysis of RANKL did not detect levels above
the detection limit (∼30 pg/ml) in any of our samples.
Next, we histologically analyzed the treatment effects on allograft healing. Although there
were no obvious effects of the first three treatments based on the appearances of the allografts,
we observed a marked amount of live new bone on the periosteal surfaces, and focally on the
endosteal surfaces of the rAAV-VEGF + rAAV-RANKL− coated allografts that was never
observed in uncoated allografts in this model (Fig. 5b-d). The presence of the new bone on the
outer surfaces of these allografts outside irregular reversal lines suggested that it had been laid
down at sites of previous resorption of the allograft periosteal bone (Fig. 5b), showing that
regions of the allografts have been partially resorbed and replaced by new bone, whereas others
were still being resorbed at the time of killing of the mice as a result of the combined therapy.
They include: (i) resorption of up to 50% of the thickness the allograft cortical bone,
predominantly from the periosteal surface, and replacement of the resorbed dead bone with
viable new bone (Fig. 5c and Fig. 6e,f), which in some cases extended the entire length of the
allograft; (ii) reversal lines that clearly delineate the depth of dead allograft resorption and the
sites of new bone formation (Fig. 6e,f), and indicate the location of a new bony union between
the live host bone and the allograft surfaces; (iii) continuing active resorption of the dead
cortical bone (Fig. 6b,d,g) with new bone formation (Fig. 6c,d,g) representative of tunneling
remodeling, which does not occur physiologically in mouse cortical bone; (iv)
neovascularization of the marrow cavity along the length of the allograft (Fig. 6e,f), in contrast
to the necrotic marrow seen in samples from the other 3 groups (Fig. 6h); and (v) the complete
absence of the fibrotic tissue reaction that typically surrounds allografts (Fig. 1g, Fig. 4g,h and
Fig. 6h) as evidenced by the thin periosteal layer between the muscle and cortical bone (Fig.
6a,f).
Considering that none of these observations was made in any of the other groups of allografted
mice we have studied (n >300), our findings provide evidence that the combination of
exogenous RANKL and VEGF can induce vascularization and remodeling of processed
structural allografts. This impression was supported by histomorphometry, which showed that
the mean cortical thickness in the rAAV-VEGF + rAAV-RANKL–coated allografts was
similar to that of the allografts that did not receive the RANKL-VEGF combination (Fig. 5b),
suggesting that this new bone must have followed the removal of up to ∼100 μm of cortical
bone. Consistent with the idea that RANKL and VEGF function in series during cortical graft
healing, we did not observe any substantial effects of transferring either one of these factors
alone. Although the resorption and new bone formation was observed in all of the mice given
rAAV-VEGF + rAAV-RANKL –coated allografts, the amount and extent of resorption and
new bone formation were variable, as evidenced by the observation that parts of some of the
grafts were being resorbed for the first time at the time of killing, 4 weeks after surgery.
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Although major progress has been made in many aspects of musculoskeletal repair
procedures19,20, including the use of bone morphogenetic proteins as adjuvants for spinal
fusion and fracture union21,22, processed structural allografts and nonremodeling bone
substitutes remain the materials of choice for reconstructive orthopedic surgery. Although bone
morphogenetic proteins represent a great advance for these indications, it has long been
recognized that they are not useful for large critical defects because of their short half-life. As
an alternative, many groups have been working on gene therapy approaches for skeletal
healing23-27. Although gene therapy offers the potential of local, sustained gene expression,
the development of a safe and effective delivery vector remains elusive28.
Over the last two decades, much work has been done to understand the critical differences
between the efficacy of live autografts and processed allografts during bone healing5,29,30.
Although these studies show that there is a host-acquired immune response to the allograft, it
is clear that the most notable difference between the two grafts is the presence of live cells in
the autograft, which directly contribute to angiogenesis and subsequent remodeling. We have
addressed two central questions to advance our understanding of these differences: what
prominent signals are present in autografts and absent in allografts that induce revascularization
and remodeling and can introduction of these signals onto the cortical surface of structural
allografts induce revascularization and remodeling? The first notable finding with the mouse
femoral graft model was that bone morphogenetic protein expression is not substantially
different between autografts and allografts. This result is somewhat contrary to the current
thinking that introducing osteogenic signals to an osteoinductive and osteoconductive
biomaterial is the best approach to improve bone healing. In contrast, our findings led us to
explore an alternative hypothesis that stimulation of resorption of the graft through
angiogenesis and osteoclast formation and activation leading to new bone formation on the
cortical surface of allografts is a superior method to improve graft incorporation. In support of
this hypothesis, we show that disruption of RANKL and VEGF signaling results in a decrease
in new bone formation on the autograft cortical surface (Fig. 3).
To evaluate gain of RANKL and VEGF function in our model, we developed a technique in
which rAAV can be immobilized to the cortical surface by freeze-drying (Fig. 4). There are
many potential methods by which rAAV could be immobilized onto the allografts, including
simple electrostatic interactions and more sophisticated bonding. Here we chose virus freeze-
drying because of its ease and practicality. Although this method does not alter the infectivity
of the virus and allows for effective transduction, the overall in vivo transduction efficiency is
modest (1–5% of cells in immediate proximity to the allograft). It is likely that this low
efficiency combined with transduction of cells that are rapidly turning over resulted in
undetectable levels of RANKL and transient elevation of VEGF concentrations in the blood
of the mice (Fig. 5a). The kinetics of the exogenous VEGF expression are also interesting from
the standpoint that the rAAV-delivered VEGF compensates for the allograft VEGF deficiency
at this crucial time point compared to autografts (Fig. 2). Despite this modest transduction, the
effects of combination gene transfer were evident and significant (Figs. 5 and 6; P < 0.05). In
so doing, we show that RANKL and VEGF are sufficient signals to markedly alter allograft
healing to generate a live, vascularized, remodeling, bony union.
In retrospect, the identification of VEGF and RANKL as critical regulators of autograft healing
in our microarray screen is not notable. In addition to its role in angiogenesis, a VEGF gradient
produced by hypertrophic chondrocytes is needed for directional growth and invasion of
cartilage by blood vessels in endochondral ossification during development11 and in fracture
healing9. Because remodeling of bone requires osteoclastic resorption, and RANKL is the final
effector molecule that differentiates mononuclear precursors into osteoclasts12, a crucial role
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of RANKL is obvious. Furthermore, it is believed that the induction of RANKL in stromal
cells in response to hypocalcemia or microfracture is the most proximal event that triggers de
novo bone remodeling12. Our microarray screen also identified many other putative players
that could similarly affect allograft healing including transcription factors, signaling molecules,
receptors and other cytokines, but further studies will be required to determine if they can
increase the efficacy of our current approach.
Here we show a new method of freeze-drying rAAV onto a surgically implantable surface,
which is a safe and effective approach that could potentially be used in other conditions in
which local delivery of gene products may be indicated. The resorption and subsequent
formation of new bone did not occur uniformly on the allograft surfaces with parts of some
allografts only being resorbed for the first time at killing, 4 weeks after surgery. This variable
response probably reflects variation in the levels and temporal expression of the target genes,
and in local tissue damage and subsequent infection of cells around the grafts. To show the
clinical utility of our coated allografts we have committed to the development of a large animal
model of structural allografting in which functional in vivo radiology can formally prove
complete vascular invasion. Biomechanical testing in this model will also be necessary to show
the advantage of remodeling versus nonremodeling allografts.
METHODS
Mouse segmental femoral graft model. All animal studies were conducted in accordance
with principles and procedures approved by the University of Rochester Committee for Animal
Resources. We used 8-week-old C57BL/6 mice for femoral grafting as we have previously
described13. We cleaned allografts from ICR mice with 70% ethanol, rinsed them three times
in saline to remove residual ethanol, and then froze them at −80 °C for at least 24 h before use.
This procedure is based on the methods used by the Musculoskeletal Transplant Foundation
to prepare clinical allografts. Graft healing was followed radiographically using a Faxitron X-
ray system as described previously15.
In vivo treatments. For loss-of-function studies with biologics, we administered antibodies
against VEGF (R&D Systems, Inc.), RANK:Fc fusion protein (a gift from Immunex, Inc.), or
goat IgG (Sigma) in phosphate-buffered saline (PBS) by intraperitoneal injection every 3 d
until mice were killed, as described previously31. Ex vivo gene transfer to live autografts were
performed by harvesting the specimen, incubating it in 20 μl of sterile PBS containing 5 ×
107 transducing units of rAAV for 10 min at room temperature and rapidly placing it back in
the original donor. We performed in vivo gene transfers to processed allografts by pipetting 5
× 107 particles of rAAV in 50 μl of a 1% sorbitol-PBS solution onto the cortical surface of the
grafts. The allografts were then frozen at −80 °C, lyophilized and stored at −80 °C until they
were transplanted. We used at least six mice in each treatment group.
Histological and histomorphometric analysis. Following killing of mice, the grafted femurs
were processed and stained with hematoxylin, eosin, Orange G and alcian blue (H&E), or for
tartrate-resistant acid phosphatase (TRAP) activity and counterstained with hematoxylin as we
have described previously31,32. We performed X-gal (Sigma) staining on sections
counterstained with eosin as we have described previously32. Histomorphometric analysis was
carried out using Osteometrics software as we have described previously13.
Real-time quantitative RT-PCR assays and microarrays. We harvested autografts and
allografts from killed mice, immediately froze them in liquid nitrogen, minced them using a
6750 Freezer/Mill (SPEX CertiPrep, Inc.), and extracted total RNA using TRIsol (Invitrogen
Corp.). We made single-stranded cDNA using a reverse transcription kit (Invitrogen) and used
it as template for real-time PCR with SYBR Green PCR Master Mix (Applied Biosystems)
Ito et al. Page 6













and gene-specific primers in a Rotor-Gene 2000 (Corbett Research) as previously
described15. The mean cycle threshold (Ct) values from quadruplicate measurements were
used to calculate the gene expression, with normalization to β-actin as an internal control. The
primer sequences for Tnfsf11 are: forward, 5′-TCTCATAACCTGATGAAAGG-3′; reverse 5′-
GCATCTTGATCCGGATCCAG-3′. The primer sequences for Vegfa are: forward, 5′-
GATGTGAATGCAGACCAAAG-3′; reverse, 5′-CACATCTGCAAGTACGTTCG-3′. The
Functional Genomics Core Facility performed the microarray experiments, under the direction
of A. Brooks. The experiments were performed by pooling the RNA extracted from six
independent samples per group (autografts or allografts) in duplicate. Total RNA from day 10
samples were biotinylated and amplified using the T7 linear amplification approach previously
described33. Affymetrix m430_2.0 arrays, which represent approximately 45,000 mouse probe
sets, were run following the manufacturer's protocol. Signal values were calculated using a
probe level analysis normalization tool (Robust Multichip Analysis, RMA) before making pair-
wise comparisons between allograft and autograft samples.
Preparation of rAAV vectors. The rAAV-β-gal34 and rAAV-OPG35 vectors have been
described previously. Plasmids containing cDNA for Vegfa36, Tnfsf11 (ref. 37) and Flt1 (ref.
38) were used for subcloning into the pAAV-BGHA transfer vector using oligonucleotide
primers containing restriction sites for NotI and EcoRI at the 5′ and 3′ end, respectively. After
ligation and transformation, positive clones grown in E. coli were confirmed by restriction
digests and DNA sequencing. The resulting plasmids were used to produce the rAAVs through
a helper-virus-free method, which were titered by dot blot39. The function of each rAAV vector
was verified by assessing protein production in vitro by enzyme-linked immunosorbent assay
(ELISA; R&S systems) as described35. The functional activities of the rAAV-RANKL and
rAAV-VEGF vectors were also confirmed by in vitro osteoclastogenesis35 and
angiogenesis40 assays, respectively. In vivo expression of VEGF and RANKL was assessed
by serum ELISA as we have described previously35. The transduction efficiency of rAAV-β-
gal was determined in vitro by X-gal staining and by assaying for β-galactosidase activity using
the Galacto-Light system (Tropix Inc.) as described previously34.
Statistical analysis. An observer blinded to the treatment performed the histomorphometry.
Data were calculated as the mean ± s.d., and the groups were compared using two-tailed
analysis of variance (ANOVA). Statistical significance was set at P < 0.05.
Accession numbers. The GEO accession numbers for the primary data files are GSM37204
and GSM37205.
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The mouse femoral allograft model. Mice received a femoral autograft or allograft, and were
killed at 3 weeks (a,c), 4 weeks (b,d,f,h) or 2 weeks (e,g). Representative radiographs from an
autografted (a,b) and an allografted (c,d) mouse are illustrated at 3 and 4 weeks after fracture.
The arrows indicate the presence of callus on the cortical surface of the autograft at 3 weeks
(a), which is remodeled by 4 weeks (b), and is completely absent in the allograft (c,d).
Hematoxylin, eosin, orange G and acian blue–stained sections show the endochondral bone
formation at the graft-host junctions (arrow heads) of both auto and allografts at 2 weeks
(e,g), which is remodeled to form a bony union at 4 weeks (f,h). Of note is the periosteal
intramembranous bone formation (*), which only occurs in autografts (e), producing a new
cortical bone collar with bone marrow at four weeks (f). In contrast, allografts are encased by
fibrous tissue (#), heal through creeping callus (g), and are dependent on dead cortical bone
for structural integrity after remodeling (h).
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Altered Tnfsf11 and Vegfa gene expression during allograft healing. Total RNA was extracted
from femoral autografts and allografts at the indicated time and processed for real time RT-
PCR. The data are presented as the fold induction ± s.d., compared to the day 0 control, after
standardization with the internal β-actin control. *P < 0.05 for autograft versus allograft at the
same time point.
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Systemic and local loss of either RANKL or VEGF results in defective autograft healing. Mice
received untreated autografts followed by injections of control IgG (a), RANK:Fc (b), or anti-
VEGF (c) therapy, and were killed four weeks later. Representative hematoxylin and eosin–
stained sections from these mice show a reduction in the amount of new bone formation around
the autographs (arrow heads) and persistence of cartilage (blue in b,c). Representative
radiographs from mice that received autografts transduced with rAAV-β-gal (e) or a
combination of rAAV-OPG and rAAV-sFlt1 (f), 2 weeks after fracture are shown.
Histomorphometry of the area of new bone formation on the autografts (d,g). *P < 0.05
compared to the IgG or rAAV-β-gal controls.
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Transduction efficiency of rAAV-β-gal following freeze-drying onto allografts and implants
in vitro and in vivo. 5 × 107 transducing units of rAAV-β-gal was lyophilized onto mouse
femoral allografts (a) or stainless steel pins (b). The transduction efficiency was determined
in vitro by incubating the coated pins on top of a monolayer of confluent 293 human embryonic
kidney cells for 72 h. Photographs of the X-gal-stained cells distal (c) and proximal (d) to the
coated pin, as well as an uncoated control pin (e) are shown. The transduction efficiency of the
coated pins was also quantified after the indicated storage time at −80 °C. RLU, relative light
units. (f). As a control, 5 × 107 transducing units of rAAV-β-gal in 50 μl PBS was directly
placed on a monolayer of 293 cells. The β-galactosidase activity in the cultures was determined
using the Galacto-Light system. No significant differences were observed. The efficiency of
in vivo transduction 14 d after transplantation is shown at ×10 (g) and ×40 (h) magnification,
where the blue staining indicates transduction of the fibroblasts (f) between the allograft (a)
and the muscle (m).
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Revitalization of processed allografts via rAAV mediated-RANKL and VEGF gene transfer.
Allografts containing 5 × 107 particles of rAAV-β-gal, rAAV-RANKL, rAAV-VEGF or a
combination of rAAV-RANKL and rAAV-VEGF were transplanted into mice and evaluated
28 d after surgery. In vivo VEGF expression was analyzed in sera taken from the combined
coated allografts at the indicated time after surgery (a). VEGF levels in uncoated allografts
were consistently >50 pg/ml throughout the time course. Representative histology from the
medial segment of the lateral cortex of a rAAV-β-gal (b) and rAAV-RANKL + rAAV-VEGF
(c) coated allograft on day 28. Of note is the considerable amount of new bone on the rAAV-
RANKL + rAAV-VEGF–coated allograft highlighted by a reversal line (arrows) and its
similarity in cortical thickness to the rAAV-β-gal coated allograft. The new bone that formed
on the allografts was quantified by histomorphometry (d) and the data are presented as the area
of new bone formation on the graft ± s.d. (*P < 0.05 versus β-gal control).
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rAAV-mediated gene transfer of RANKL and VEGF induces cortical bone resorption,
vascularization and remodeling in processed allografts in vivo. Representative TRAP-stained
histologic sections from mice in the combination group (a–d). An example of a rAAV-VEGF
+ rAAV-RANKL–coated allograft in which remodeled bone extends the entire length of the
graft (arrow heads) is shown (a). The novel histologic features of the combination group were
characterized by osteoclastic resorption of the necrotic bone (black arrows in b,d,g),
osteoblastic new bone formation in the resorption lacunae (white arrows in c,d) and osteoclastic
remodeling of the new woven bone (yellow arrows in d). Hematoxylin and eosin–stained
sections of allografts from the combination group revealed asymmetric reversal lines (dashed
line in e and shown at higher magnification without the lines in g, and black arrow in c) between
dead bone and newly formed live bone, new blood vessel formation inside the marrow cavities
(* in e,f), and active tunneling resorption (arrows in f) in the necrotic bone. In contrast, none
of the other groups showed these features and were all characterized by a fibrotic tissue (f) that
covered the periosteal surface and necrotic tissue (n) that filled the marrow cavity (h).
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